To study the safety and efficacy of Pegaptanib eye injection in the treatment of retinal bleeding due to myopia
- Conditions
- Health Condition 1: null- Myopic Choroidal Neovascular Memberane
- Registration Number
- CTRI/2011/07/001919
- Lead Sponsor
- VPrasad Eye Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
1.Should be willing to participate in the trial.
2.Age less than 55 years.
3.Best corrected visual acuity (BCVA) score of at least 5 letters (20/200), as assessed by ETDRS chart.
4.Myopia of greater than or equal to 6 Diopters.
5.Fluorescein angiographic documentation of CNV.
1.Ocular causes, or other ocular disorders leading to vision loss.
2.Maculopathy not related to pathologic myopia.
3.Pregnancy, lactation.
4.Not willing to provide an informed consent.
5.History of previous macular laser including PDT.
6.Other forms of therapy including intravitreal injections.
7.History of intraocular surgery in the past 3 months.
8.Anticipated cataract surgery in the next 6 months.
9.Any active infection or inflammation in the eye.
10.Cases where good quality imaging is not possible, either due to hazy media or extremely high myopia.
11.Patients with uncontrolled glaucoma, with IOP 21mm Hg on 2 or more medications.
12.Patients with subfoveal scar or significant subretinal haemorrhage occupying more than 50% of lesion size.
13.Eyes with previous retinal detachment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method